Preliminary Evaluation of the Diagnostic Usefulness of Uroplakin 2 with an Assessment of the Antioxidant Potential of Patients with Bladder Cancer

Table 4

GSH level in the plasma in patients BC and control group.

Groups	GSH in plasma [μM]
	Mean	SD	p-value
BC	5.14	2.02	p=0.047; BC vs C
C	6.04	2.05
NMIBC	5.23	2.08	p=0.451; NMIBC vs MIBC
MIBC	4.85	2.08
LG	5.31	2.42	p=0.507; LG vs HG
HG	4.95	1.62
M	5.32	2.05	p=0.129; M vs W
W	4.23	2.06
Non-smoking patients	4.66	2.45	p=0.403; non-smoking vs smoking
Smoking patients	5.25	1.99

BC: patients group; C: control group; NMIBC: non-muscle invasive BC; MIBC: muscle invasive BC; LG: low grade; HG: high grade; M: men; W: women; SD: standard deviation; p: statistically significant difference.